---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-017616"
form_type: "8-K"
ticker: "VTAK"
cik: "0001716621"
company_name: "Catheter Precision, Inc."
filed_at: "2025-05-19T23:59:59+00:00"
generated_at: "2026-05-21T01:50:40.767310+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Catheter Precision Q1 revenue up 74% to $143K, net loss $4.0M; cash $450K

## Summary
- Revenue $143K vs $82K YoY (+74%); net loss $4.0M including $1.2M non-cash charges.
- Cash $450K at March 31; after quarter end secured $1.5M private placement from institutional investors.
- Acquired Cardionomics assets via 82%-owned subsidiary Cardionomix, including CPNS system for ADHF.
- Acquired PeriKard, LLC (pericardial access kit); first U.S. patent allowed for LockeT device.
- Clinical data presented at HRS 2025: VIVO 94% accurate, LockeT safe/effective in 139-patient study.

## SEC filing metadata
- accession: 0001437749-25-017616
- form_type: 8-K
- ticker: VTAK
- cik: 0001716621
- company_name: Catheter Precision, Inc.
- filed_at: 2025-05-19T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716621/000143774925017616/0001437749-25-017616-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716621/000143774925017616/vtak20250519_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-017616
- JSON: https://secwatch.observer/filing/0001437749-25-017616.json
- Plain text: https://secwatch.observer/filing/0001437749-25-017616.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.